ArticleCommunications biology2025
HSPA4 restrains transferrin in dopaminergic neurons to attenuate ferroptosis in a Parkinson's disease model.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- DDIT4 silencing attenuates sevoflurane-induced ferroptosis via the mTOR pathway in neuronal cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Metabolic Mechanisms of Hexavalent Chromium-Induced Splenic Immune Injury via Oxidative Stress and Ferroptosis Pathways in New Zealand Rabbits.Metabolites · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Heat shock protein A4 (HSPA4) is a molecular chaperone belonging to the heat shock protein 70 (HSP70) family. This study aims to investigate the antiferroptotic effects of HSPA4 in a Parkinson's disease (PD) model and explore the underlying mechanisms. Here we show that HSPA4 overexpression reduces ferroptosis in erastin-treated SH-SY5Y cells and primary dopaminergic neurons, while HSPA4 knockdown exacerbates ferroptosis. In MPTP-induced PD model mice, HSPA4 rectifies behavioral defects, prevents the loss of dopaminergic neurons, and alleviates ferroptosis. Mechanistically, HSPA4 interacts with transferrin in the cytoplasm and inhibits its export from the cell. Consequently, extracellular iron cannot be transported into cells due to a lack of transferrin, thereby attenuating ferroptosis in dopaminergic neurons and slowing PD progression. By restraining transferrin in dopaminergic neurons, HSPA4 reduces ferroptosis and alleviates parkinsonism in a PD mouse model. Therefore, HSPA4 might present a potential therapeutic target for the development of PD treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.